Intended for healthcare professionals


Depression: EU approves expanded use of esketamine for rapid reduction of symptoms

BMJ 2021; 372 doi: (Published 10 February 2021) Cite this as: BMJ 2021;372:n398
  1. Elisabeth Mahase
  1. The BMJ

Esketamine nasal spray—sold under the name Spravato—has been approved by the European Commission as a short term treatment for adults with a moderate to severe episode of major depressive disorder.1

The spray, which must be given alongside an oral antidepressant, has been approved for use in situations deemed a psychiatric emergency, to reduce depressive symptoms rapidly.

The treatment was initially approved by the …

View Full Text

Log in

Log in through your institution


* For online subscription